The clinicopathologic diversity of BRAFV600E-mutated CNS tumors due to diverse co-occurring alterations makes treatment decisions ambiguous and raises the need for preclinical testing of combination therapies of BRAF/MEK inhibitors and therapies targeting co-occurring alterations. This evidence concerns the gene BRAF and central nervous system neoplasm.